1. Search Result
Search Result
Results for "

Organoids

" in MedChemExpress (MCE) Product Catalog:

35

Inhibitors & Agonists

2

Biochemical Assay Reagents

2

Peptides

53

MCE Kits

2

Inhibitory Antibodies

2

Natural
Products

2

Click Chemistry

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P1454
    Fz7-21
    3 Publications Verification

    Ac-LPSDDLEFWCHVMY-NH2

    Wnt Cancer
    Fz7-21 (Ac-LPSDDLEFWCHVMY-NH2) is a potent peptide antagonist of FZD7 receptors , selectively binds to FZD7 CRD subclass and alters the conformation of the CRD and the architecture of its lipid-binding groove. The EC50 values are 58 and 34 nM for human and mouse FZD7 CRD, respectively. Fz7-21 impairs the function of FZD7 in Wnt–β-catenin signalling and stem cell function in intestinal organoids .
    Fz7-21
  • HY-P1454A
    Fz7-21 TFA
    3 Publications Verification

    Ac-LPSDDLEFWCHVMY-NH2 TFA

    Wnt Cancer
    Fz7-21 (Ac-LPSDDLEFWCHVMY-NH2) TFA is a potent peptide antagonist of FZD7 receptors , selectively binds to FZD7 CRD subclass and alters the conformation of the CRD and the architecture of its lipid-binding groove. The EC50 values are 58 and 34 nM for human and mouse FZD7 CRD, respectively. Fz7-21 TFA impairs the function of FZD7 in Wnt-β-catenin signalling and stem cell function in intestinal organoids .
    Fz7-21 TFA
  • HY-115579
    MALAT1-IN-1
    3 Publications Verification

    DNA/RNA Synthesis Cancer
    MALAT1-IN-1 (compounds 5) is a potent and specific Malat1 (Metastasis-associated lung adenocarcinoma transcript 1) inhibitor. MALAT1-IN-1 modulated Malat1 downstream genes in a dose-dependent manner without affecting expression of nuclear enriched abundant transcript 1 (Neat1) .
    MALAT1-IN-1
  • HY-112484
    RS-246204
    1 Publications Verification

    Organoid Cancer
    RS-246204 is a R-spondin-1 substitute compound that is able initiate small intestinal organoids without the use of the R-spondin-1 protein.
    RS-246204
  • HY-156088

    Apoptosis Microtubule/Tubulin Mitosis Cancer
    SSE1806 is a derivative of podophyllotoxin (a natural antimitotic agent) and a microtubule/tubulin inhibitor with significant anticancer and antiproliferative activities. The GI50 of SSE1806 on cancer cell growth ranges from 1.29-21.15 μM. SSE1806 causes mitotic abnormalities and G2/M phase arrest, increases p53 expression, and inhibits colon cancer organoid growth. SSE1806 is able to overcome multidrug resistance in cell lines overexpressing MDR-1 .
    SSE1806
  • HY-161346

    PROTACs Epigenetic Reader Domain Cancer
    EBET-1055 is a bromodomain and extra-terminal (BET) protein degrader (EBET) composed of a BET inhibitor (EBET-590, HY-161387), an E3 ubiquitin ligase ligand and connectors. EBET-1055 effectively inhibits the growth of pancreatic ductal adenocarcinoma (PDAC). EBET-1055 also simultaneously modulates cancer-associated fibroblast (CAF) activity, upregulating all reporter gene activities in organoid co-cultures .
    EBET-1055
  • HY-175201

    LPL Receptor STAT Cancer
    pro-FTY, a FTY720 (HY-12005) anticancer prodrug, is a sphingosine-1-phosphate (S1P) (HY-108496) inhibitor. pro-FTY specifically inhibits S1P signaling in cancer cells using a drug delivery system (DDS) that reacts with acrolein. pro-FTY significantly inhibits the survival of breast cancer cells, including multidrug-resistant cells and its organoids resistant to Paclitaxel (HY-B0015) or Doxorubicin (HY-15142A). pro-FTY potently suppresses tumor growth in 4T1 cells or organoids xenograft tumors mice model while avoiding lymphocytopenia .
    pro-FTY
  • HY-155246

    Apoptosis PARP Cancer
    PARP1-IN-15 (Compound 6) is a PARP1 inhibitor. PARP1-IN-15 inhibits tankyrase (TNKS) and facilitates DNA double-strand breaks damage. PARP1-IN-15 induces tumor cell apoptosis. PARP1-IN-15 has anti-cancer activity in triple-negative breast cancer (TNBC) cells and TNBC patient-derived organoids. PARP1-IN-15 can be used for research of TNBC with or without BRCA1 mutations .
    PARP1-IN-15
  • HY-162955

    HDAC Histone Demethylase Cancer
    LSD1/HDAC-IN-1 (compound 2) is a potent inhibitor of HDAC and LSD1, with IC50s of 0.125 nM, 0.373 nM, 0.0118 nM, 0.103 nM, and 0.571 μM for HDAC1, HDAC2, HDAC6, HDAC8 and LSD1, respectively. LSD1/HDAC-IN-1 plays an important role in cancer research .
    LSD1/HDAC-IN-1
  • HY-169098

    HSP Histone Demethylase Cancer
    HSP90/LSD1-IN-1 (compound 6) is a HSP90/LSD1 dual inhibitor. HSP90/LSD1-IN-1 inhibits the proliferation of prostate cancer cell lines PC-3 and DU145, with GI50 values ​​of 0.24 and 0.30 μM, respectively .
    HSP90/LSD1-IN-1
  • HY-168875

    TrxR Reactive Oxygen Species (ROS) Cancer
    TrxR1 prodrug-1 (compound 5u) is a potent inhibitor of TrxR1. TrxR1 prodrug-1 exhibits significant antitumor efficiency in nude mice and NSCLC organoids .
    TrxR1 prodrug-1
  • HY-173349

    PARP Cancer
    TDI-012804 is a TNKS2 inhibitor that selectively inhibits intracellular endogenous TNKS2 protein. TDI-012804 increases the expression of AXIN1 protein in cells that are heterozygous (Tnks1HET) and completely knocks out (Tnks1KO) for TNKS1. TDI-012804 inhibits the proliferation of ApcQ1405X/Tnks1KO organoids (EC50 of 59.1 nM) and is selectively toxic to Tnks1KO AKP-G12D and AKP-G13D organoids .
    TDI-012804
  • HY-169797

    STAT Survivin Apoptosis Cancer
    STAT3-IN-38 (Compound 4m) is an inhibitor of STAT3 (KD of rhSTAT3: 45.33  µM). STAT3-IN-38 binds to the SH2 domain of STAT3 protein and suppresses the STAT3’s phosphorylation at site pTyr705 as well as its downstream genes (Survivin and Mcl-1). STAT3-IN-38 could block cell-cycle and induce Apoptosis in colorectal cancer cells .
    STAT3-IN-38
  • HY-163743

    Salt-inducible Kinase (SIK) Cancer
    SIC-19 is a SIK2 inhibitor and promotes SIK2 protein degradation via the ubiquitination pathway. SIC-19 inhibits cancer cell growth and sensitizes cells to PARP inhibitors (Such as Olaparib (HY-10162)), as well as in ovarian cancer organoids and xenograft models .
    SIC-19
  • HY-174300

    Pregnane X Receptor (PXR) Metabolic Disease
    Cholic acid-Glu is a derivative of Cholic acid (HY-N0324). The abundance of Cholic acid-Glu is increased in Crohn’s disease. Cholic acid-Glu increases PXR activation and significantly increases the expression of the downstream PXR target gene Cyp3a11 in small intestinal organoid tissue .
    Cholic acid-Glu
  • HY-162351

    Emopamil Binding Protein Metabolic Disease
    EBP-IN-1 (compound 11) is an inhibitor of emopamil-binding protein (EBP), a sterol isomerase in the cholesterol biosynthetic pathway. EBP-IN-1 has a long half-life in rodents and has good metabolic turnover and brain penetration properties. EBP-IN-1 enhances oligodendrocyte formation in human cortical organoids .
    EBP-IN-1
  • HY-150042

    YAP Cardiovascular Disease Others
    TDI-011536 is a potent Lats kinase inhibitor, interrupts Hippo-Yap signaling and initiates the proliferation of lesioned heartmuscle cells. TDI-011536 can be used in studies of organ conservation and regeneration .
    TDI-011536
  • HY-N3855

    Autophagy Apoptosis Cancer
    Erythrabyssin II (EL-19) is a potent late-stage autophagy inhibitor that blocks the fusion of autophagosome and lysosome. Erythrabyssin II leads to the accumulation of autophagic substrates and does not impair lysosomal pH or lysosomal enzyme activity. Erythrabyssin II suppresses ovarian cancer organoid activity and induces apoptosis. Erythrabyssin II can be used for the study of ovarian cancer .
    Erythrabyssin II
  • HY-168884

    mTOR Metabolic Disease
    AV457 is a potent and selective mTOR inhibitor with an IC50 value of 0.54 µM. AV457 inhibits cyst growth in polycystic kidney disease (PKD) organoids. AV457 decreases the protein expression of P-s6, P-p70s6 and don’t decreases the protein expression of P-AKT .
    AV457
  • HY-168260

    Apoptosis Ferroptosis MMP Cancer
    CQ-Mito is a Coumarin-Quinazolinone (CQ)-based derivative that targets mitochondria and exhibits profound phototherapeutic performances with an Phototoxic Index (PI) value of 167. CQ-Mito causes cell death by both apoptosis and ferroptosis. CQ-Mito mediates mitochondrial dysfunction, including mitochondrial morphology changed and the loss of MMP. CQ-Mito can efficiently inhibit the tumor growth in organoid tumor models .
    CQ-Mito
  • HY-147165

    YAP Cancer
    VT02956 is a LATS inhibitor (IC50: 0.76 nM for LATS1, 0.52 nM for LATS2). VT02956 targets the Hippo pathway. VT02956 inhibits ESR1 expression and growth of ER+ breast cancer cell lines and patient-derived tumor organoids . VT02956 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    VT02956
  • HY-W009310

    Endogenous Metabolite Organoid Others
    9-cis-Retinal is a natural retinoid. Dietary 9-cis-β-carotene generates 9-cis-retinoids via cleavage into 9-cis-retinal. 9-cis Retinal binds to cellular retinol-binding protein-I (CRBP-I) and CRBP-II with Kds of 8 nM and 5 nM, respectively. 9-cis-Retinal expedites differentiation and maturation of rod photoreceptors in retinal organoids .
    9-cis-Retinal
  • HY-147105

    Orphan Receptor Inflammation/Immunology
    LRH-1 modulator-1 (compound 6N) is a potent LRH-1 (liver receptor homolog-1) modulator/agonist. LRH-1 modulator-1 shows anti-inflammatory effects in intestinal organoids. LRH-1 modulator-1 induces anti-inflammatory cytokine IL-10, and reduces inflammatory cytokine IL-1b and TNFa .
    LRH-1 modulator-1
  • HY-147165A

    YAP Cancer
    VT02956 is a LATS inhibitor (IC50: 0.76 nM for LATS1, 0.52 nM for LATS2). VT02956 targets the Hippo pathway. VT02956 inhibits ESR1 expression and growth of ER+ breast cancer cell lines and patient-derived tumor organoids . VT02956 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    VT02956 hydrochloride
  • HY-153190A

    Ferroptosis STAT Cancer
    W1131 TFA is a potent STAT3 inhibitor that induces ferroptosis. W1131 inhibits cancer progression in subcutaneous xenograft, organoid, and PDX models of gastric cancer. W1131 effectively alleviates cancer cell chemoresistance to 5-FU (HY-90006). W1131 regulates the cell cycle, DNA damage response, and oxidative phosphorylation, including the IL6-JAK-STAT3 pathway and the ferroptosis pathway .
    W1131 TFA
  • HY-162627

    Lactate Dehydrogenase Cancer
    LDHA-IN-6 (compound 6) is an oral bioactive inhibitor of lactate dehydrogenase-A (LDHA), with the IC50 of 46 nM. LDHA-IN-6 has antitumor activity .
    LDHA-IN-6
  • HY-153190

    Oxidative Phosphorylation STAT Ferroptosis Cancer
    W1131 is a potent STAT3 inhibitor, triggering ferroptosis. W1131 suppresses cancer progression in gastric cancer cell subcutaneous xenograft model, organoids model, and PDX model. W1131 effectively alleviates chemical resistance of cancer cells to 5-FU (HY-90006). W1131 regulates cell cycle, DNA damage response, and oxidative phosphorylation, including IL6-JAK-STAT3 pathway and ferroptosis pathway .
    W1131
  • HY-147082
    GA-017
    3 Publications Verification

    YAP Cancer
    GA-017 is a potent and selective LATS1 and LATS2 (large tumor suppressor kinase 1/2) inhibitor, with IC50 values of 4.10 and 3.92 nM, respectively. GA-017 is an activator of cell proliferation. GA-017 promotes YAP/TAZ activation and nuclear translocation. GA-017 promotes cell growth under 3D culture conditions. GA-017 enhances the ex vivo formation of mouse intestinal organoids .
    GA-017
  • HY-158220

    HAMA (MW 400 kDa)

    Biochemical Assay Reagents Others
    Hyaluronic acid Methacryloyl (HAMA) is methacrylated hyaluronic acid that is biocompatible. Hyaluronic acid Methacryloyl is also used as a 3D printing hydrogel ink, which has the characteristics of fast photosensitive response, fast gelation speed and stable hydrogel performance. Hyaluronic acid Methacryloyl can quickly induce gelation with lithium phenyl-2,4,6-trimethylbenzoylphosphinate (LAP) under UV irradiation. The combination of Hyaluronic acid Methacryloyl and tissue-specific extracellular matrix (ECM) materials (such as pancreatic extracellular matrix (pECM)) will become an important source material for organoid culture .
    Hyaluronic acid Methacryloyl (MW 400 kDa)
  • HY-158220A

    HAMA (MW 150 kDa)

    Biochemical Assay Reagents Others
    Hyaluronic acid Methacryloyl (HAMA) MW 150 kDa is methacrylated hyaluronic acid that is biocompatible. Hyaluronic acid Methacryloyl is also used as a 3D printing hydrogel ink, which has the characteristics of fast photosensitive response, fast gelation speed and stable hydrogel performance. Hyaluronic acid Methacryloyl can quickly induce gelation with lithium phenyl-2,4,6-trimethylbenzoylphosphinate (LAP) under UV irradiation. The combination of Hyaluronic acid Methacryloyl and tissue-specific extracellular matrix (ECM) materials (such as pancreatic extracellular matrix (pECM)) will become an important source material for organoid culture .
    Hyaluronic acid Methacryloyl (MW 150 kDa)
  • HY-147105A

    Interleukin Related Inflammation/Immunology
    (+)-LRH-1 modulator-1 is a stereoisomer of LRH-1 modulator-1. LRH-1 modulator-1 (compound 6N) is a potent LRH-1 (liver receptor homolog-1) modulator/agonist. LRH-1 modulator-1 has anti-inflammatory effects in intestinal organoids. LRH-1 modulator-1 induces the anti-inflammatory cytokine IL-10 and reduces the inflammatory cytokines IL-1b and TNFa .
    (+)-LRH-1 modulator-1
  • HY-163801

    Nuclear Hormone Receptor 4A/NR4A Neurological Disease
    Nurr1 agonist 9 (Compound 36) is an agonist for Nurr1 with an EC50 of 0.090 µM and a Kd of 0.17 µM. Nurr1 agonist 9 activates the Nurr1 homodimer (NurRE, EC50=0.094 µM) and the Nurr1-RXR heterodimer (DR5, EC50=0.165 µM). Nurr1 agonist 9 induces the expression of Nurr1-regulated tyrosine hydroxylase (TH) in organoid Parkinson's Disease model. Nurr1 agonist 9 is human brain endothelial cell barrier prmeable .
    Nurr1 agonist 9
  • HY-P990173

    PD-1/PD-L1 Inflammation/Immunology Cancer
    Anti-Mouse/Rat/Human PD-L1 Antibody (368A.4H1) is a mouse-derived PD-L1 IgG1 κ type antibody inhibitor. Anti-Mouse/Rat/Human PD-L1 Antibody (368A.4H1) increases IFN-γ levels in organoid-primed T cells. Anti-Mouse/Rat/Human PD-L1 Antibody (368A.4H1) can be used for the researches of cancer, such as oral squamous cell carcinoma and mammary cancer .
    Anti-Mouse/Rat/Human PD-L1 Antibody (368A.4H1)
  • HY-P99011

    CD3 Cancer
    Cibisatamab, a T cell bispecific antibody, binds Carcino-Embryonic Antigen (CEA) on cancer cells and CD3 on T cells. Cibisatamab triggers T cell killing of cancer cell lines expressing moderate to high levels of CEA at the cell surface. Cibisatamab can be used for colorectal cancer research .
    Cibisatamab
  • HY-176220

    AUTACs Autophagy Glutathione Peroxidase Ferroptosis
    GPX4-AUTAC is a GPX4-targeting autophagy-mediated degrader (AUTAC). GPX4-AUTAC consists of an inhibitor ML162-yne (HY-153748), a degradation tag FBnG (HY-W073762) and a glycol linker (HY-W021401). GPX4-AUTAC promotes the ubiquitination of GPX4 by E3 ligase TRAF6, and enhances the binding with GPX4 and p62, leading to the selective autophagy-dependent degradation of GPX4. GPX4-AUTAC significantly induces ferroptosis and shows a potent anti-cancer activity in breast cancer cells, breast cancer-derived organoids (PDOs) and MDA-MB-231 tumor xenograft mice model, with potent synergistic effects when combined with Sulfasalazine (SAS) (HY-14655) or chemotherapy drugs (Paclitaxel (HY-B0015) or Cisplatin (HY-17394)) .
    GPX4-AUTAC

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: